Abstract: Background: Literature regarding acute human toxicity of mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) is limited. Objectives: Our objectives were to describe all cases of overdose with MMF or EC-MPS reported to the Swiss Toxicological Information Centre (STIC) or in the literature between 1995 and 2013. Therefore, we performed an observational case-series and systematic literature search to determine circumstances, magnitude, management and outcome of overdose with MMF or EC-MPS. Results: Of 152,762 reports to STIC, 15 (7 pediatric) involved overdose with MMF (n = 13) or EC-MPS (n = 2). Three cases from other centers were identified from a systematic literature search. The magnitude of overdose ranged from 1.2 to 16.7 (median 2.9) times usual dose. Six (33%) MMF overdoses had attributable symptoms, which included abdominal pain, vomiting, headache and dizziness. The majority of findings were minor, although a 9-fold MMF overdose caused hypotension 8 h after ingestion and a 12.5-fold overdose caused leukopenia after 5 days. Symptoms did not occur in patients who took 2.5 times or less of their usual MMF dose. Gastrointestinal decontamination measures with activated charcoal were undertaken in one-third of cases. Conclusions: Acute MMF and EC-MPS overdoses had a favorable outcome in all cases reported to STIC and in the literature. Six (33%) MMF overdoses had attributable symptoms which included abdominal pain, vomiting, headache and dizziness. The majority of findings were minor, although a 9-fold MMF overdose caused hypotension 8 h after ingestion and a 12.5-fold overdose caused leukopenia after 5 days. Symptoms did not occurr in patients who took 2.5-times or less of their usual MMF dose. Gastrointestinal decontamination measures with activated charcoal were undertaken in one third of cases.
Introduction
Mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS) are selective immunosuppressants used in combination with other immunosuppressive agents for the prevention of acute rejection after solid organ transplantation in adults and children 1, 2 . They are also used in the treatment of several autoimmune diseases 3 . Compared to the frequently prescribed thiopurines, these are newer active substances which have been approved for use in Switzerland since 1995 (MMF) and 2002 (EC-MPS). MMF is the prodrug and EC-MPS the sodium salt of the active substance mycophenolic acid (MPA). The term MPA will be used when discussing toxicity because it is the active form of both drugs.
MPA is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) 4 .
IMPDH is the rate-limiting enzyme in the synthesis of guanosine nucleotides. As T-and Blymphocyte-proliferation is entirely dependent on the de novo synthesis of guanosine (unlike other cell types which can utilise guanosine from a salvage pathway), MPA exerts a much more potent cytostatic effect on lymphocytes than on other cell types 4 . The most frequently reported side effects of MPA are gastrointestinal disturbances, which are dose-dependent and include nausea, diarrhoea, anorexia, abdominal cramps and vomiting. Reversible, doserelated haematological effects such as anaemia, leukopenia neutropenia and thrombocytopenia are also observed 5 . The long term therapeutic use of MMF and EC-MPS appears to be safe and not to show any serious consequences 6, 7 .
MMF is rapidly absorbed and de-esterified to MPA after oral administration; the absolute bioavailability of MPA is 94%. Intravenous administration of MMF leads to a comparable exposure as observed after oral administration of the same dose 1 . EC-MPS is readily absorbed in the small intestine because its enteric coating dissolves at pH 5.5. The ingestion of equimolar doses of MMF and EC-MPS lead to similar peak concentrations and exposure, and the degree of IMPDH inhibition is also comparable. The intra-and interpatient pharmacokinetic variability is high for both MPA formulations 8, 9 .
The majority of MPA is metabolized in the liver by UDP-glycuronosyltransferases [UGT] in a phase II glucuronidation process. MPA is converted to a major 7-O-glucuronide metabolite (MPAG) which is pharmacologically inactive 10 . MPAG is excreted into bile and therefore back into the bowel where gut bacteria can deglucuronidate it to reform MPA which is reabsorbed. This enterohepatic recirculation results in a `second peak` approximately 6 -8 hours after ingestion, which could add to or prolong toxicity. In addition to MPAG, two other metabolites, MPA-acyl-glucoronide (AcMPAG) and MPA-phenyl-glucoside (glucoside-MPA), are observed in plasma 11 . In vitro analysis has shown that AcMPAG is pharmacologically active and is likely responsible for the gastrointestinal toxicity of MPA 12 . Approximately 93% of the glucuronide metabolites are renally excreted 10 .
Patients taking MMF or EC-MPS may be intentionally or accidentally exposed to acute overdose. In addition, their household contacts may have access to these drugs and also be at risk of overdose. The purpose of this study was to investigate the circumstances, management and outcomes of overdoses with MMF or EC-MPS using data reported to a single national poison centre and data reported in the literature during an 18-year period.
Methods

Study design
Specific ethics approval was not required for this observational study due to the nature of the study design in accordance with the regulations of the cantonal ethics committee Zurich, Switzerland which also stated that anonymised data generated during patient care can be used retrospectively for research purposes without obtaining written consent. We performed a retrospective review of all acute overdoses involving MMF or EC-MPS in adults and children (<16 years) either alone or in combination with other drugs that had been reported to the Swiss Toxicological Information Centre (STIC) between April 1995 and August 2013 (for further details, see the online supplement). Cases were assigned an internal identification number so neither the patients or caregivers nor the reporting professionals could be identified by the investigators.
A systematic literature-search was performed in MEDLINE and EMBASE from 1995 to 2013 using the terms `mycophenolate` (which encompases mycophenolate sodium, mycophenolic acid and mycophenolate mofetil) and `overdose`. Furthermore the relevant product information 1, 2 and guidance on the management of acute overdose 13, 14 were examined.
Circumstances and symptoms of overdose
The circumstances of overdose were categorised into `suicidal` for cases of intentional overdose, `domestic` for cases of accidental overdose in the home and `iatrogenic` for those due to a prescribing or administration error by a healthcare professional. The drug half-life was calculated according to the standard pharmacokinetic equation given in the online supplement in cases where serial drug concentration measurements had been performed
Results
Cases
A total of 152,762 reports by healthcare professionals to the STIC of confirmed or suspected overdose with any substance occurred during the study period. Of these, 13 were with MMF and two with EC-MPS (7 paediatric cases). In 14 cases the route of administration was oral (tablets, capsules or oral solution) while in one case MMF was administrated as an intravenous solution. The majority of the cases were reported by hospital doctors (n=13), one case by another doctor and one case by a caregiver. Demographic characteristics, circumstances of overdose, the magnitude of overdose and the availability of follow-up data are given in Table 1 along with the details of three cases published in the literature [20] [21] [22] .
Adults and children are presented separately. Table 2 shows the details of each individual case. For the cases reported to STIC, the mean age of adult cases was 31.5 years (range 19-50). Six (40%) cases involved patients already receiving immunosuppression, eight cases (53%) did not normally receive immunosuppression and in one case the underlying diagnosis was not known. Six (86%) of the seven accidental domestic overdoses were in children (age range 1.5-9 years). Four of these were living with parents or siblings undergoing treatment with MMF or EC-MPS. One case of dosing error in the home (patient 13) involved a mother administering 2 ml of dry MMF powder to her child rather than reconstituting the powder with water and administering 2 ml of the resulting solution as per instructions. The cases labelled `15`, `16` and `17` in tables 2 and 3 are those which have been published previously [20] [21] [22] . All three were females with an underlying diagnosis requiring immunosuppression. In two cases (patients 15 and 16) the overdose was deliberate (with suicidal intent) while in patient 17 the overdose was caused iatrogenically during a drug switch from twice daily MMF to once daily EC-MPS in an attempt to improve adherence (although EC-MPS is licensed to be given every 12 hours 2 ). Therapeutic drug monitoring showed a significantly higher drug exposure after once daily 1.44 g enteric-coated EC-MPS than under the previous MMF 1 g twice-daily dose 22 . The dose of EC-MPS was subsequently reduced to 900 mg once daily. Table 3 shows the magnitude of overdose in relation to the patient`s usual maintenance dose or -for treatment-naïve individuals -in relation to the maximum licensed dose. Two of the exposures were retrospectively found to be equal to or less than the maximum licensed dose and were a case of accidental ingestion by a child (patient 2) and a case of iatrogenic error (patient 18). These two cases were considered `accidental exposures within the therapeutic range` rather than `overdose` and were not included in the analysis of symptom development in order to accurately reflect the effect of true overdose. The overdoses ranged from 1.2 to 16.7 times the usual or maximum licensed dose (Table 2) . 
Magnitude of overdose
Pharmacokinetic calculations
The half-lives of MPA were 2.6 h and 6.1 h in patients 15 and 16, respectively. By reading raw data points off the concentration-time graph in the publication describing patient 17 22 , an estimated half-life of 7.4 h after ingestion of EC-MPS could be calculated.
Outcomes
The outcomes of overdose are given in detail in 
Management
Of the cases reported to STIC, three patients were discharged home on the same day of presentation either immediately after initial evaluation in the emergency room or after a brief period of observation. All three were asymptomatic. Five patients were admitted to acute medical wards (one subsequently self-discharged against medical advice). Of those hospitalised, median length of hospital stay was 1 day (range 1-2). Hospitalisation status was unknown in 4 patients. Care was transferred from acute medical to psychiatric in-patient services in one case.
The recommendation for use and subsequent use of decontamination measures is shown in Table 3 . Of the cases reported to STIC, decontamination measures with activated charcoal were performed in four cases; all of which were children who presented to emergency services within one hour of ingestion. In three patients it is not known if any action was performed. However, the administration of activated charcoal was recommended in two of these cases. Decontamination with activated charcoal was also performed in the paediatric patient who experienced accidental exposure within the therapeutic range (patient 2). For the patients who did not receive activated charcoal, median time until presentation to emergency services was two hours (range <1 -5.5 h). A follow-up blood count was performed in 1 case of MMF overdose (patient 7, one day after overdose) with a normal result.
Among the cases reported in the literature, patient 15 presented to the emergency room 4 hours after ingestion and was treated with activated charcoal and supportive care
(promethazine for nausea and intravenous fluids). She was hospitalized, but the length of stay was not specified 21 . Patient 16 presented to the emergency room approximately 10 hours after ingestion, where she was treated with activated charcoal and oral cholestyramine 
Discussion
This case-series analysis of MMF and EC-MPS overdoses reported to a single national poison centre between 1995 and 2013 adds a further 15 cases to the three case reports currently published in the medical literature. Acute overdoses of these substances are rare and seem to be generally well tolerated. As the experience with acute overdose of MMF and EC-MPS in humans is very limited, the data presented here gives an insight into the patterns, management strategies and outcomes of MMF and EC-MPS overdoses.
Circumstances of overdose
A number of important issues emerge when examining the circumstances of overdose with MMF or EC-MPS. In contrast to our previous findings for calcineurin inhibitor (CNI) overdose where iatrogenic errors accounted for 46% of the reported cases 17 , iatrogenic dosing errors only accounted for 2 (11%) of all the cases presented here. This may be due to the fact that liquid formulations (intravenous or oral), which accounted for almost three quarters of the CNI iatrogenic overdoses, are much less commonly used for the administration of MMF, and EC-MPS is only available in tablet form. Nonetheless, extra vigilance should be paid when dealing with such drug forms, as mistakes can easily be made when procedures are unfamiliar. This also holds true for people who take responsibility for drug administration in the home, in particular parents, who should be clearly instructed how to reconstitute powder to make an oral solution. The majority (75%) of MMF and EC-MPS overdoses in adults were with suicidal intent. This is in accordance with the proportion reported in the medical literature to date where 2 of the 3 reports were cases of suicidal intent. Both patients suffered from a chronic condition requiring immunosuppression 20, 21 . The number of accidental overdoses in the home was also higher than for the previously reported CNI and thiopurine overdose series: 47% in the current series compared to 11% among CNI overdoses and 30% among thiopurine overdoses 17, 18 which further emphasises the need to repeatedly instruct patients to keep medicines out of reach of unintended recipients.
Magnitude and Outcomes
MMF overdose was associated with symptoms in a dose-dependent manner. These were mainly headache or gastrointestinal-related and were minor in nature. Gastrointestinal symptoms such as nausea, vomiting, diarrhoea or cramping are also the most common adverse effects of these active substances when given in therapeutic doses 1 . One case of haemodynamically significant hypotension occurred 8 hours after ingestion. This is in keeping with the enterohepatic recycling of MPAG, which means a second peak MPA concentration is reached approximately 6 -12 hours after oral ingestion 1 . The mechanism underlying mycophenolate-induced hypotension is not known.
Patient 16 was found to be leukopenic 14 hours after overdose 20 . Whether this was due to the overdose is not certain as the leukocyte count had not been measured during the days and weeks immediately preceding the overdose and she was also receiving quetiapine, an agent known to be frequently (> 10%) associated with leukopenia 24 . In our opinion, the mechanism whereby MPA causes leukopenia (disruption of de novo guanosine synthesis) is unlikely to lead to such a rapid decline in the leukocyte count and it is likely that the leukocyte count was already decreased prior to overdose in this particular case. After overdose in this patient, the leukocyte count continued to fall, reaching a nadir 5 days later.
The oral acute lethal dose 50 (LD50) for MMF in rats is 352 mg/kg, in mice 1000 mg/kg and >6000 mg/kg in rabbits, indicating a species-dependence of the lethal dose 25 . The maximum overdose in this current series was 448 mg/kg.
Pharmacokinetics:
The apparent half-life of MPA is 16 -18 hours; an accurate determination of MPA`s half-life is hampered by MPAG`s enterohepatic recirculation 1, 10 . In the literature cases studied here, terminal half-life was 2.6 h in a case where activated charcoal was given 4 hours after overdose (Patient 15), 6.1 h in a case where activated charcoal and cholestyramine were given 10 h after overdose (patient 16) and 7.4 h (patient 17). These data imply a reduction in the MPA half-life when activated charcoal alone or in combination with cholestyramine is used in the management of MMF overdose. A study of liver transplant patients, however, also found a shorter terminal disposition half-life (mean 4.54 ± 1.19 h) than the pharmacokinetic studies in healthy volunteers 26, 10 . Unlike concomitant cyclosporin, tacrolimus (the calcineurin inhibitor used in this study) is not known to disrupt the enterohepatic cycling of MPAG so this cannot explain the shorter half-life seen 1 .
Management
Due to the rarity of MMF and EC-MPS overdoses, it is not possible to perform randomised controlled trials to determine the optimal management, and examination of case data such as that presented here is therefore important.
Patients who ingested 2.5 times or less than their usual or the maximum recommended MMF or EC-MPS dose did not develop symptoms and medical treatment or hospitalisation of such cases (other than for psychiatric reasons) does not appear to be indicated. Similarly, in our opinion, activated charcoal should only be used in cases of definite overdose as its administration is not without risk 27 . The fact that activated charcoal was only administrated to children in the cases reported to STIC most likely reflects their earlier presentation to emergency services (all within 1 h -table 3).
In this case-series, patients who received activated charcoal developed fewer symptoms.
However, it is not possible to conclude a definite beneficial effect of activated charcoal after mycophenolate overdose as these patients had presented earlier and had ingested, on average, smaller doses than patients who did not receive activated charcoal.
The Swiss product information for MMF and EC-MPS do not recommend the use of activated charcoal after overdose 1, 2 . Other sources, however, recommend that activated charcoal be used `early` in overdose of these drugs 14 and that it is most effective when administered within 1 h of overdose 13 . On the basis of their chemical properties, a good adsorption of MMF and EC-MPS onto activated charcoal is to be expected. MMF and EC-MPS have molecular weights of 433 and 320 Dalton respectively 28 , which means that they are readily adsorbed into the 10-20 Å-sized charcoal pores 29 . As the absolute bioavailability of MPA after oral administration of MMF is high (94%) and MPA reaches its peak plasma concentration between 1.5 and 2 hours after ingestion 1 , it is reasonable to expect that activated charcoal is beneficial when administered within 2 hours after overdose. One can also speculate that charcoal administered later than 2 hours would still be of benefit because it could reduce the `second peak` resulting from reabsorption of MPAG excreted in the bile, thereby minimising the effect of the enterohepatic recirculation. In the cases published by Bebarta and Wu, activated charcoal was given 4 and 10 hours after overdose, respectively 21, 20 , and the half-lives were found to be less than expected. This provides some evidence to support the use of activated charcoal beyond 2 hours after overdose in MMF and EC-MPS overdose.
The administration of bile acid sequestrants, such as cholestyramine, is recommended in the treatment of acute overdose with MMF or EC-MPS in the Swiss product information 1, 2 but not specifically by the widely consulted Poisindex® Database 13 . By binding parent and glucuronidated drug that is excreted in the bile, cholestyramine prevents their reabsorption and deglucuronidation, respectively and thereby interrupts the enterohepatic recycling of Interestingly the STIC case in which hypotension was observed eight hours after overdose had neither been treated with activated charcoal nor with cholestyramine. This case also illustrates the point that it would seem prudent to monitor patients who have ingested large MMF or EC-MPS doses or who are symptomatic at presentation for at least 12 -24 hours after overdose due to the possible risk of delayed hypotension.
Limitations
Our study has a number of limitations, primarily related to the small sample size. Larger series of MMF or EC-MPS overdoses have, however, not been published. It is likely that our data did not capture all cases of overdose which occurred in the referral population. Our data are also incomplete, which is the nature of retrospective studies using poison centre data 30 .
Unfortunately, a number of cases were lost to follow-up despite repeated efforts of the STIC to contact the treating physicians in the days after presentation. In some cases follow-up took place sooner than 7 days after overdose which is the time point when maximum bone marrow suppression after ingestion of a bone marrow suppressing agent such as MMF and EC-MPS might be expected. A further limitation is the paucity of data regarding blood or plasma concentrations which would have allowed stronger conclusions regarding pharmacokinetic-pharmacodynamic relationships and the effect of decontamination on drug absorption to be drawn. However, such data are extremely difficult to obtain as therapeutic drug monitoring for MMF and EC-MPS are not routinely performed.
Conclusion
Acute MMF and EC-MPS overdoses occurred commonly in the context of suicide attempt among adults and in the context of accidental poising in the home among children. The acute overdoses were well tolerated, with the exception of a 9-fold MMF overdose which was associated with hypotension eight hours after ingestion possibly reflecting the enterohepatic circulation of MPAG and a case of moderate leukopenia 5 days after a 12.5-fold overdose.
More data are needed to determine the effect of decontamination with activated charcoal and cholestyramine. MMF and EC-MPS overdose patterns, outcomes and management require further study and physicians should be encouraged to actively follow-up and report the cases in which they are involved.
